Nintedanib hits targets in rare lung disease trial
The drug was successful in patients with systemic sclerosis associated interstitial lung disease.
Read More
Tag: nintedanib
PIM status for Boehringer’s mesothelioma drug
Boehringer Ingelheim’s nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency.
Read More
US/EU orphan status for BI’s Ofev in systemic sclerosis
US and EU regulators have granted Orphan Drug Designation to Boehringer Ingelheim’s Ofev for the treatment of systemic sclerosis, including the associated interstitial lung disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
